Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents

Bristol-Myers Squibb

Overview

A retrospective study to evaluate healthcare cost and resource utilization for patients with metastatic renal cell carcinoma who have been treated with IV or oral agents

Study Type

OBSERVATIONAL

Conditions

Renal Cell Carcinoma

Interventions

Non-InterventionalOTHER

Other

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis with metastatic renal cell carcinoma * Prescription/administration of one of the IV or oral agents examined in the study Exclusion Criteria: * Patients with other primary cancer diagnosis before RCC diagnosis * Patients with pregnancy or HIV/AIDS

Locations (1)

Bristol-Myers Squibb

Princeton, New Jersey, United States

Outcomes

Primary Outcomes

Distribution of Healthcare costs for patients treated with oral drugs used in the first-line treatment of Metastatic renal cell carcinoma (mRCC)

All-cause healthcare costs will be calculated in the first-line oral cohort as per-patient-per-month (PPPM) costs.

Time frame: Up to 63 months

Composite of Resource Utilization for patients treated with oral drugs used in the first-line treatment of mRCC

Total numbers and rates of inpatient, outpatient, and emergency room visits per patient will be calculated.

Time frame: Up to 63 months

Distribution of Healthcare costs for patients treated with IV drugs used in the first-line treatment of mRCC

All-cause healthcare costs will be calculated in the first-line IV cohort as per-patient-per-month (PPPM) costs.

Time frame: Up to 63 months

Composite of Resource Utilization for patients treated with IV drugs used in the first-line treatment of mRCC

Total numbers and rates of inpatient, outpatient, and emergency room visits per patient will be calculated.

Time frame: Up to 63 months

Secondary Outcomes

Medication Possession Ratio (MPR) for patients treated with oral drugs used in the first-line treatment of mRCC

MPR will be calculated for each index drug as the ratio of the sum of the total number of days' supply to the total number of days in the follow-up period.

Time frame: Up to 63 months

Medication Possession Ratio (MPR) for patients treated with IV drugs used in the first-line treatment of mRCC

MPR will be calculated for each index drug as the ratio of the sum of the total number of days' supply to the total number of days in the follow-up period.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.